Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
17,819
archived clinical trials in
Brain Cancer

PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors
Phase I and Pharmacokinetic Trial of PTC299 in Pediatric Patients With Refractory or Recurrent CNS Tumors
Status: Archived
Children's Hospital - Boston
mi
from
Boston, MA
PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors
Phase I and Pharmacokinetic Trial of PTC299 in Pediatric Patients With Refractory or Recurrent CNS Tumors
Status: Archived
Updated: 1/1/1970
Children's Hospital - Boston
mi
from
Boston, MA
PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors
Phase I and Pharmacokinetic Trial of PTC299 in Pediatric Patients With Refractory or Recurrent CNS Tumors
Status: Archived
Duke Univ Med Ctr
mi
from
Durham, NC
PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors
Phase I and Pharmacokinetic Trial of PTC299 in Pediatric Patients With Refractory or Recurrent CNS Tumors
Status: Archived
Updated: 1/1/1970
Duke Univ Med Ctr
mi
from
Durham, NC
PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors
Phase I and Pharmacokinetic Trial of PTC299 in Pediatric Patients With Refractory or Recurrent CNS Tumors
Status: Archived
Children's Hospital at Downstate
mi
from
Brooklyn, NY
PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors
Phase I and Pharmacokinetic Trial of PTC299 in Pediatric Patients With Refractory or Recurrent CNS Tumors
Status: Archived
Updated: 1/1/1970
Children's Hospital at Downstate
mi
from
Brooklyn, NY
PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors
Phase I and Pharmacokinetic Trial of PTC299 in Pediatric Patients With Refractory or Recurrent CNS Tumors
Status: Archived
St. Jude Childrens Research Hosp, Memphis
mi
from
Memphis, TN
PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors
Phase I and Pharmacokinetic Trial of PTC299 in Pediatric Patients With Refractory or Recurrent CNS Tumors
Status: Archived
Updated: 1/1/1970
St. Jude Childrens Research Hosp, Memphis
mi
from
Memphis, TN
PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors
Phase I and Pharmacokinetic Trial of PTC299 in Pediatric Patients With Refractory or Recurrent CNS Tumors
Status: Archived
Texas Children's Hospital - Feigin Center
mi
from
Houston, TX
PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors
Phase I and Pharmacokinetic Trial of PTC299 in Pediatric Patients With Refractory or Recurrent CNS Tumors
Status: Archived
Updated: 1/1/1970
Texas Children's Hospital - Feigin Center
mi
from
Houston, TX
A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
A Phase I Study of IMC-A12 (Anti-Insulin-like Growth Factor-I Receptor Monoclonal Antibody) in Combination With CCI-779 (Temsirolimus) in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Archived
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
A Phase I Study of IMC-A12 (Anti-Insulin-like Growth Factor-I Receptor Monoclonal Antibody) in Combination With CCI-779 (Temsirolimus) in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Archived
Updated: 1/1/1970
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
A Phase I Study of IMC-A12 (Anti-Insulin-like Growth Factor-I Receptor Monoclonal Antibody) in Combination With CCI-779 (Temsirolimus) in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Archived
University of Minnesota Medical Center
mi
from
Minneapolis, MN
A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
A Phase I Study of IMC-A12 (Anti-Insulin-like Growth Factor-I Receptor Monoclonal Antibody) in Combination With CCI-779 (Temsirolimus) in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Archived
Updated: 1/1/1970
University of Minnesota Medical Center
mi
from
Minneapolis, MN
A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
A Phase I Study of IMC-A12 (Anti-Insulin-like Growth Factor-I Receptor Monoclonal Antibody) in Combination With CCI-779 (Temsirolimus) in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Archived
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
A Phase I Study of IMC-A12 (Anti-Insulin-like Growth Factor-I Receptor Monoclonal Antibody) in Combination With CCI-779 (Temsirolimus) in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Archived
Updated: 1/1/1970
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
A Phase I Study of IMC-A12 (Anti-Insulin-like Growth Factor-I Receptor Monoclonal Antibody) in Combination With CCI-779 (Temsirolimus) in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Archived
Nationwide Children's Hospital in Columbus
mi
from
Columbus, OH
A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
A Phase I Study of IMC-A12 (Anti-Insulin-like Growth Factor-I Receptor Monoclonal Antibody) in Combination With CCI-779 (Temsirolimus) in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Archived
Updated: 1/1/1970
Nationwide Children's Hospital in Columbus
mi
from
Columbus, OH
A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
A Phase I Study of IMC-A12 (Anti-Insulin-like Growth Factor-I Receptor Monoclonal Antibody) in Combination With CCI-779 (Temsirolimus) in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Archived
Baylor School of Medicine
mi
from
Houston, TX
A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
A Phase I Study of IMC-A12 (Anti-Insulin-like Growth Factor-I Receptor Monoclonal Antibody) in Combination With CCI-779 (Temsirolimus) in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Archived
Updated: 1/1/1970
Baylor School of Medicine
mi
from
Houston, TX
A Phase 1/2 Study of PF-02341066, An Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and C-Met, in Children With Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma
A Phase 1/2 Study of PF-02341066, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and C-Met, in Children With Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma
Status: Archived
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
A Phase 1/2 Study of PF-02341066, An Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and C-Met, in Children With Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma
A Phase 1/2 Study of PF-02341066, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and C-Met, in Children With Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma
Status: Archived
Updated: 1/1/1970
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
A Phase 1/2 Study of PF-02341066, An Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and C-Met, in Children With Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma
A Phase 1/2 Study of PF-02341066, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and C-Met, in Children With Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma
Status: Archived
Children's Hospital of Wisconsin
mi
from
Milwaukee, WI
A Phase 1/2 Study of PF-02341066, An Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and C-Met, in Children With Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma
A Phase 1/2 Study of PF-02341066, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and C-Met, in Children With Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma
Status: Archived
Updated: 1/1/1970
Children's Hospital of Wisconsin
mi
from
Milwaukee, WI
Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases
BAFETINIB-P1-GBM-01: A Pilot Study Using Intracerebral Microdialysis to Determine the Neuropharmacokinetics of Bafetinib in Patients With Recurrent Brain Tumors
Status: Archived
City of Hope Medical Canter
mi
from
Duarte, CA
Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases
BAFETINIB-P1-GBM-01: A Pilot Study Using Intracerebral Microdialysis to Determine the Neuropharmacokinetics of Bafetinib in Patients With Recurrent Brain Tumors
Status: Archived
Updated: 1/1/1970
City of Hope Medical Canter
mi
from
Duarte, CA
Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases
BAFETINIB-P1-GBM-01: A Pilot Study Using Intracerebral Microdialysis to Determine the Neuropharmacokinetics of Bafetinib in Patients With Recurrent Brain Tumors
Status: Archived
City of Hope Medical Group Inc
mi
from
Pasadena, CA
Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases
BAFETINIB-P1-GBM-01: A Pilot Study Using Intracerebral Microdialysis to Determine the Neuropharmacokinetics of Bafetinib in Patients With Recurrent Brain Tumors
Status: Archived
Updated: 1/1/1970
City of Hope Medical Group Inc
mi
from
Pasadena, CA
RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia
A Phase 1/2 Study of RO4929097, An Oral Small Molecule Inhibitor of Gamma-Secretase, in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia
Status: Archived
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia
A Phase 1/2 Study of RO4929097, An Oral Small Molecule Inhibitor of Gamma-Secretase, in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia
Status: Archived
Updated: 1/1/1970
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia
A Phase 1/2 Study of RO4929097, An Oral Small Molecule Inhibitor of Gamma-Secretase, in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia
Status: Archived
St. Jude Childrens Research Hosp, Memphis
mi
from
Memphis, TN
RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia
A Phase 1/2 Study of RO4929097, An Oral Small Molecule Inhibitor of Gamma-Secretase, in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia
Status: Archived
Updated: 1/1/1970
St. Jude Childrens Research Hosp, Memphis
mi
from
Memphis, TN
Exploratory Study of XL765 or XL147 in Subjects With Recurrent Glioblastoma Who Are Candidates for Surgical Resection
An Exploratory Pharmacodynamic Study of XL765 and XL147 Administered as Single Agents to Subjects With Recurrent Glioblastoma Who Are Candidates for Surgical Resection
Status: Archived
David Geffen School of Medicine, UCLA
mi
from
Los Angeles, CA
Exploratory Study of XL765 or XL147 in Subjects With Recurrent Glioblastoma Who Are Candidates for Surgical Resection
An Exploratory Pharmacodynamic Study of XL765 and XL147 Administered as Single Agents to Subjects With Recurrent Glioblastoma Who Are Candidates for Surgical Resection
Status: Archived
Updated: 1/1/1970
David Geffen School of Medicine, UCLA
mi
from
Los Angeles, CA
Exploratory Study of XL765 or XL147 in Subjects With Recurrent Glioblastoma Who Are Candidates for Surgical Resection
An Exploratory Pharmacodynamic Study of XL765 and XL147 Administered as Single Agents to Subjects With Recurrent Glioblastoma Who Are Candidates for Surgical Resection
Status: Archived
Unversity of California, San Francisco
mi
from
San Francisco, CA
Exploratory Study of XL765 or XL147 in Subjects With Recurrent Glioblastoma Who Are Candidates for Surgical Resection
An Exploratory Pharmacodynamic Study of XL765 and XL147 Administered as Single Agents to Subjects With Recurrent Glioblastoma Who Are Candidates for Surgical Resection
Status: Archived
Updated: 1/1/1970
Unversity of California, San Francisco
mi
from
San Francisco, CA
Exploratory Study of XL765 or XL147 in Subjects With Recurrent Glioblastoma Who Are Candidates for Surgical Resection
An Exploratory Pharmacodynamic Study of XL765 and XL147 Administered as Single Agents to Subjects With Recurrent Glioblastoma Who Are Candidates for Surgical Resection
Status: Archived
Dana-Farber Cancer Institute
mi
from
Boston, MA
Exploratory Study of XL765 or XL147 in Subjects With Recurrent Glioblastoma Who Are Candidates for Surgical Resection
An Exploratory Pharmacodynamic Study of XL765 and XL147 Administered as Single Agents to Subjects With Recurrent Glioblastoma Who Are Candidates for Surgical Resection
Status: Archived
Updated: 1/1/1970
Dana-Farber Cancer Institute
mi
from
Boston, MA
The Treatment and Natural History of Acromegaly
Acromegaly Treatment and Natural History
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
The Treatment and Natural History of Acromegaly
Acromegaly Treatment and Natural History
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Genetic Analysis of Brain Tumors
A Prospective National Study to Molecularly and Genetically Characterize Human Gliomas: The Glioma Molecular Diagnostic Initiative
Status: Enrolling
Updated:  12/31/1969
Thomas Jefferson University
mi
from
Philadelphia, PA
Genetic Analysis of Brain Tumors
A Prospective National Study to Molecularly and Genetically Characterize Human Gliomas: The Glioma Molecular Diagnostic Initiative
Status: Enrolling
Updated: 12/31/1969
Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Genetic Analysis of Brain Tumors
A Prospective National Study to Molecularly and Genetically Characterize Human Gliomas: The Glioma Molecular Diagnostic Initiative
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Genetic Analysis of Brain Tumors
A Prospective National Study to Molecularly and Genetically Characterize Human Gliomas: The Glioma Molecular Diagnostic Initiative
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Genetic Analysis of Brain Tumors
A Prospective National Study to Molecularly and Genetically Characterize Human Gliomas: The Glioma Molecular Diagnostic Initiative
Status: Enrolling
Updated:  12/31/1969
Columbia University
mi
from
New York, NY
Genetic Analysis of Brain Tumors
A Prospective National Study to Molecularly and Genetically Characterize Human Gliomas: The Glioma Molecular Diagnostic Initiative
Status: Enrolling
Updated: 12/31/1969
Columbia University
mi
from
New York, NY
Click here to add this to my saved trials
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma
Status: Enrolling
Updated:  12/31/1969
Mercy Medical Center - Sioux City
mi
from
Sioux City, IA
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma
Status: Enrolling
Updated: 12/31/1969
Mercy Medical Center - Sioux City
mi
from
Sioux City, IA
Click here to add this to my saved trials
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma
Status: Enrolling
Updated:  12/31/1969
Cancer Center of Kansas, PA - Chanute
mi
from
Chanute, KA
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma
Status: Enrolling
Updated: 12/31/1969
Cancer Center of Kansas, PA - Chanute
mi
from
Chanute, KA
Click here to add this to my saved trials
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma
Status: Enrolling
Updated:  12/31/1969
Cancer Center of Kansas, PA - Dodge City
mi
from
Dodge City, KA
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma
Status: Enrolling
Updated: 12/31/1969
Cancer Center of Kansas, PA - Dodge City
mi
from
Dodge City, KA
Click here to add this to my saved trials
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma
Status: Enrolling
Updated:  12/31/1969
Cancer Center of Kansas, PA - El Dorado
mi
from
El Dorado, KA
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma
Status: Enrolling
Updated: 12/31/1969
Cancer Center of Kansas, PA - El Dorado
mi
from
El Dorado, KA
Click here to add this to my saved trials
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma
Status: Enrolling
Updated:  12/31/1969
Cancer Center of Kansas - Fort Scott
mi
from
Fort Scott, KA
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma
Status: Enrolling
Updated: 12/31/1969
Cancer Center of Kansas - Fort Scott
mi
from
Fort Scott, KA
Click here to add this to my saved trials
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma
Status: Enrolling
Updated:  12/31/1969
Cancer Center of Kansas-Independence
mi
from
Independence, KA
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma
Status: Enrolling
Updated: 12/31/1969
Cancer Center of Kansas-Independence
mi
from
Independence, KA
Click here to add this to my saved trials
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma
Status: Enrolling
Updated:  12/31/1969
Cancer Center of Kansas, PA - Kingman
mi
from
Kingman, KA
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma
Status: Enrolling
Updated: 12/31/1969
Cancer Center of Kansas, PA - Kingman
mi
from
Kingman, KA
Click here to add this to my saved trials
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma
Status: Enrolling
Updated:  12/31/1969
Lawrence Memorial Hospital
mi
from
Lawrence, KA
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma
Status: Enrolling
Updated: 12/31/1969
Lawrence Memorial Hospital
mi
from
Lawrence, KA
Click here to add this to my saved trials
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma
Status: Enrolling
Updated:  12/31/1969
Cancer Center of Kansas, PA - Liberal
mi
from
Liberal, KA
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma
Status: Enrolling
Updated: 12/31/1969
Cancer Center of Kansas, PA - Liberal
mi
from
Liberal, KA
Click here to add this to my saved trials
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma
Status: Enrolling
Updated:  12/31/1969
Cancer Center of Kansas, PA - Newton
mi
from
Newton, KA
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma
Status: Enrolling
Updated: 12/31/1969
Cancer Center of Kansas, PA - Newton
mi
from
Newton, KA
Click here to add this to my saved trials
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma
Status: Enrolling
Updated:  12/31/1969
Cancer Center of Kansas, PA - Parsons
mi
from
Parsons, KA
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma
Status: Enrolling
Updated: 12/31/1969
Cancer Center of Kansas, PA - Parsons
mi
from
Parsons, KA
Click here to add this to my saved trials
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma
Status: Enrolling
Updated:  12/31/1969
Cancer Center of Kansas, PA - Pratt
mi
from
Pratt, KA
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma
Status: Enrolling
Updated: 12/31/1969
Cancer Center of Kansas, PA - Pratt
mi
from
Pratt, KA
Click here to add this to my saved trials
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma
Status: Enrolling
Updated:  12/31/1969
Cancer Center of Kansas, PA - Salina
mi
from
Salina, KA
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma
Status: Enrolling
Updated: 12/31/1969
Cancer Center of Kansas, PA - Salina
mi
from
Salina, KA
Click here to add this to my saved trials
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma
Status: Enrolling
Updated:  12/31/1969
Associates in Women's Health
mi
from
Wichita, KA
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma
Status: Enrolling
Updated: 12/31/1969
Associates in Women's Health
mi
from
Wichita, KA
Click here to add this to my saved trials
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma
Status: Enrolling
Updated:  12/31/1969
Wichita CCOP
mi
from
Wichita, KA
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma
Status: Enrolling
Updated: 12/31/1969
Wichita CCOP
mi
from
Wichita, KA
Click here to add this to my saved trials
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma
Status: Enrolling
Updated:  12/31/1969
Cancer Center of Kansas-Wichita Medical Arts Tower
mi
from
Wichita, KA
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma
Status: Enrolling
Updated: 12/31/1969
Cancer Center of Kansas-Wichita Medical Arts Tower
mi
from
Wichita, KA
Click here to add this to my saved trials
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma
Status: Enrolling
Updated:  12/31/1969
Via Christi Regional Medical Center
mi
from
Wichita, KA
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma
Status: Enrolling
Updated: 12/31/1969
Via Christi Regional Medical Center
mi
from
Wichita, KA
Click here to add this to my saved trials
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma
Status: Enrolling
Updated:  12/31/1969
Cancer Center of Kansas, PA - Winfield
mi
from
Winfield, KA
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma
Status: Enrolling
Updated: 12/31/1969
Cancer Center of Kansas, PA - Winfield
mi
from
Winfield, KA
Click here to add this to my saved trials
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma
Status: Enrolling
Updated:  12/31/1969
Hurley Medical Center
mi
from
Flint, MI
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma
Status: Enrolling
Updated: 12/31/1969
Hurley Medical Center
mi
from
Flint, MI
Click here to add this to my saved trials
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma
Status: Enrolling
Updated:  12/31/1969
Saint John Macomb-Oakland Hospital
mi
from
Warren, MI
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma
Status: Enrolling
Updated: 12/31/1969
Saint John Macomb-Oakland Hospital
mi
from
Warren, MI
Click here to add this to my saved trials
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma
Status: Enrolling
Updated:  12/31/1969
Fairview Ridges Hospital
mi
from
Burnsville, MN
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma
Status: Enrolling
Updated: 12/31/1969
Fairview Ridges Hospital
mi
from
Burnsville, MN
Click here to add this to my saved trials
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma
Status: Enrolling
Updated:  12/31/1969
Fairview Southdale Hospital
mi
from
Edina, MN
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma
Status: Enrolling
Updated: 12/31/1969
Fairview Southdale Hospital
mi
from
Edina, MN
Click here to add this to my saved trials
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma
Status: Enrolling
Updated:  12/31/1969
Hutchinson Area Health Care
mi
from
Hutchinson, MN
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma
Status: Enrolling
Updated: 12/31/1969
Hutchinson Area Health Care
mi
from
Hutchinson, MN
Click here to add this to my saved trials
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma
Status: Enrolling
Updated:  12/31/1969
United Hospital
mi
from
Saint Paul, MN
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma
Status: Enrolling
Updated: 12/31/1969
United Hospital
mi
from
Saint Paul, MN
Click here to add this to my saved trials
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma
Status: Enrolling
Updated:  12/31/1969
Ridgeview Medical Center
mi
from
Waconia, MN
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma
Status: Enrolling
Updated: 12/31/1969
Ridgeview Medical Center
mi
from
Waconia, MN
Click here to add this to my saved trials
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma
Status: Enrolling
Updated:  12/31/1969
Bozeman Deaconess Cancer Center
mi
from
Bozeman, MT
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma
Status: Enrolling
Updated: 12/31/1969
Bozeman Deaconess Cancer Center
mi
from
Bozeman, MT
Click here to add this to my saved trials
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma
Status: Enrolling
Updated:  12/31/1969
Northern Montana Hospital
mi
from
Havre, MT
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma
Status: Enrolling
Updated: 12/31/1969
Northern Montana Hospital
mi
from
Havre, MT
Click here to add this to my saved trials